Hepatitis A and B vaccine

Hepatitis A and B vaccine

Combined hepatitis A and B vaccine (Twinrix)
Combination of
Hepatitis A vaccine	Vaccine
Hepatitis B vaccine	Vaccine
Clinical data
Trade names	Twinrix, Ambirix, others
AHFS/Drugs.com	FDA Professional Drug Information
License data	US DailyMed: Hepatitis_a_and_hepatitis_b
Pregnancy category	AU: B2
Routes of administration	Intramuscular
ATC code	J07BC20 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) UK: POM (Prescription only) US: ℞-only EU: Rx-only
Identifiers
CAS Number	467420-42-4 Y
ChemSpider	none
UNII	5BFC8LZ6LQ

Combined hepatitis A and B vaccine, is used to provide protection against hepatitis A and hepatitis B. It is given by injection into muscle.

It is used in areas where hepatitis A and B are endemic, for travelers, people with hepatitis C or chronic liver disease, and those at high risk of sexually transmitted diseases.

The combined vaccine is as safe and protective as if given as separate hepatitis A and B vaccines. It is generally well-tolerated. Common side effects are mild and include redness and pain at the injection site, where a small lump may appear. Feeling faint or tired, or a headache may occur. Other side effects include numbness, tingling, rash, bruising, abnormal bleeding such as from the nose or gums, weak muscle or pain. Severe side effects are rare and include an allergic reaction and seizures.

It is widely available.

Administration schedule

Routine Twinrix vaccination is administered by intramuscular injection in the deltoid area using a schedule of three separate doses at 0, 1, and 6 months ([minimum intervals: 4 weeks between doses 1 and 2, 5 months between doses 2 and 3]). In some circumstances, an accelerated dosing schedule of 0, 7 and 21 to 30 days followed by a booster at 12 months can be used and was shown to have similar efficacy as the traditional schedule.

Efficacy

The U.S. Centers for Disease Control and Prevention (CDC) reports that clinical trials found the following levels of protection against Hepatitis A and Hepatitis B one month after each dose:

A: 93.8%, 98.8%, 99.9%

B: 30.8%, 78.2%, 98.5%

GlaxoSmithKline claims that its studies found 70% of subjects had antibodies against hepatitis B a month after just the first dose, however.Twinrix should not be used for postexposure prophylaxis, because no data are available on the efficacy of combination vaccine for prophylaxis after exposure to HAV.

Availability

Twinrix is a brand manufactured by GlaxoSmithKline Biologicals. The full generic name is hepatitis A inactivated & hepatitis B (recombinant) vaccine. Twinrix is administered over three doses. The name was created because it is a mixture of two earlier vaccines — Havrix, an inactivated-virus Hepatitis A vaccine, and Engerix-B, a recombinant Hepatitis B vaccine. Twinrix first entered the market in early 1997.

In the United States, Twinrix is approved by the Food and Drug Administration (FDA) for those aged 18 and older. In some countries outside the United States, notably Canada and in the European Union, Twinrix is known as Twinrix Adult or Ambirix and a pediatric formulation, called Twinrix Junior or Twinrix Paediatric, is available.

Society and culture

Economics

By being a combination it may reduce administrative costs and achieve a better uptake of the vaccine.

Names

Brand names include Twinrix, Twinrix Junior, Twinrix paediatric, Ambirix, and Bilive.

External links

• "Twinrix". Food and Drug Administration (FDA). 3 October 2019.